<DOC>
	<DOCNO>NCT00308932</DOCNO>
	<brief_summary>To determine effect age device delivery HFA-Fluticasone Propionate ( FP ) child different age . Hypothesis -- passive inhalation young child valved hold chamber/mask ( VHC ) reduce relative amount FP deliver airway .</brief_summary>
	<brief_title>Effect Age Device Delivery Fluticasone</brief_title>
	<detailed_description>The objective determine effect age device delivery fluticasone propionate deliver HFA-pMDI child different age . The one-hour steady-state fluticasone plasma concentration indirect measure airway delivery direct measure systemic exposure , determine . Sixty child well-controlled persistent asthma receive two actuation 110 mcg twice daily least 3 day . A blood sample collect one hour last dose 100 % adherence document electronic monitor . Five group 12 study : 1 ) 12-18 yr actuator alone ; 2 ) 5-9 yr actuator alone ; 3 ) 5-9 yr antistatic VHC/mouthpiece ; 4 ) 5-9 yr antistatic VHC/mask 5 ) 1-4 yr antistatic VHC/mask . Fluticasone concentration measure LC-MS/MS assay . Fluticasone plasma concentration group compare use one way ANOVA .</detailed_description>
	<mesh_term>Asthma</mesh_term>
	<mesh_term>Fluticasone</mesh_term>
	<criteria>child 118 yr , adequately control persistent asthma , demonstrate effective administration technique accordance group assign inadequately control asthma : nocturnal awaken &gt; 2 nights/month , prn albuterol use &gt; 2x/week , 2 short course oral corticosteroid previous 3 month , miss dose one occasion , increase asthma symptom study , inability discontinue intranasal dermal fluticasone 3 day</criteria>
	<gender>All</gender>
	<minimum_age>1 Year</minimum_age>
	<maximum_age>18 Years</maximum_age>
	<verification_date>August 2004</verification_date>
	<keyword>fluticasone</keyword>
	<keyword>asthma therapy</keyword>
	<keyword>spacer inhaler</keyword>
	<keyword>HFA-134a</keyword>
</DOC>